This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK)
In a report released yesterday, from Guggenheim reiterated a Buy rating on ProKidney, with a price target of $7.00. The company’s shares closed yesterday at $2.08.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProKidney has an analyst consensus of Hold, with a price target consensus of $5.75, which is a 176.44% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
Based on ProKidney’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $217 thousand and a GAAP net loss of $16.47 million. In comparison, last year the company had a GAAP net loss of $17.91 million
Read More on PROK:
Disclaimer & DisclosureReport an Issue
- ProKidney reports Q4 EPS (52c), consensus (15c)
- Optimized PROACT 1 Design, Preserved Statistical Power, and Clear Regulatory Path Support Buy Rating on ProKidney
- ProKidney: Preserved Long-Term Opportunity but Heightened Timeline Risk Supports Continued Hold Rating
- ProKidney Expands Phase 3 REGEN-006 Trial Enrollment Plans
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
